NUOVE INDICAZIONI RIMBORSATE DI TRASTUZUMAB DERUXTECAN: G.U. del 20 dicembre 2023
MONARCH 3: Risultati dell’analisi finale della sopravvivenza globale presentati al San Antonio Breast Cancer Symposium (SABCS) il 6 dicembre 2023 (09/01/2024)
STUDIO NATALEE. RIBOCICLIB ADIUVANTE NEL CARCINOMA MAMMARIO (19/12/2023)
STUDIO NATALEEE: ribociclib adiuvante nel carcinoma mammario (12/12/2023)
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial. (05/12/2023)
Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US (28/11/2023)
Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US (14/11/2023)
Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US (novembre 2023)
US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer (aprile 2023)
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial (aprile 2023)
Intra-individual comparison of ¹⁸F-sodium fluoride PET–CT and ⁹⁹mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial (febbraio 2023)
MARGITUXIMAB vs TRASTUZUMAB in pazienti con carcinoma mammario HER2-positivo avanzato pretrattato: risultati dello studio randomizzato di fase III SOPHIA (febbraio 2023)
